SomaLogic Partners with Agilent to Distribute Proteomic Technology
Summary
SomaLogic also has a development deal with Quest Diagnostics, and the first product they plan to work on together is a blood test for early detection of non-small cell lung cancer.The agreement with Agilent will promote and sell SOMAscan, the biomarker discovery platform SomaLogic developed in order to create diagnostic tools.“This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market,” Jacob Thaysen, vice president and general manager of Agilent’s Genomics Solutions Division, said in a statement.The deal will allow academic centers and contract researchers to acquire what is essentially “a clone” of the technology SomaLogic uses in Boulder, Steele wrote.“Our goal is to have the first couple operational as soon as possible, though [it] may be several months.” The platform’s applications include biomarker discovery and drug development, and interest looks strong enough to build a consistent revenue stream, Steele said.
Classifications
AskAI Classifications
LabelsLinked Companies
